Publications Repository

Publications Repository

View Item 
  •   Home
  • ICR Divisions
  • Other ICR Research
  • View Item
  • Home
  • ICR Divisions
  • Other ICR Research
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.

Thumbnail
View/Open
Accepted version (528.9Kb)
ICR Author
Banerjee, Susana
Marsden,
Author
George, A
Kaye, S
Banerjee, S
Type
Journal Article
Metadata
Show full item record
Abstract
The treatment of patients with ovarian cancer is rapidly changing following the success of poly [ADP-ribose] polymerase (PARP) inhibitors in clinical trials. Olaparib is the first PARP inhibitor to be approved by the EMA and FDA for BRCA-mutated ovarian cancer. Germ line BRCA mutation status is now established as a predictive biomarker of potential benefit from treatment with a PARP inhibitor; therefore, knowledge of the BRCA status of an individual patient with ovarian cancer is essential, in order to guide treatment decisions. BRCA testing was previously offered only to women with a family or personal history of breast and/or ovarian cancer; however, almost 20% of women with high-grade serous ovarian cancer are now recognized to harbour a germ line BRCA mutation, and of these, >40% might not have a family history of cancer and would not have received BRCA testing. A strategy to enable more widespread implementation of BRCA testing in routine care is, therefore, necessary. In this Review, we summarize data from key clinical trials of PARP inhibitors and discuss how to integrate these agents into the current treatment landscape of ovarian cancer. The validity of germ line BRCA testing and other promising biomarkers of homologous-recombination deficiency will also be discussed.
URL
https://repository.icr.ac.uk/handle/internal/659
Collections
  • Other ICR Research
Licenseref URL
http://www.rioxx.net/licenses/all-rights-reserved
Version of record
10.1038/nrclinonc.2016.191
Subject
Clinical Trials as Topic
Female
Genes, BRCA1
Genes, BRCA2
Genetic Testing
Germ-Line Mutation
Humans
Models, Genetic
Ovarian Neoplasms
Poly(ADP-ribose) Polymerase Inhibitors
Language
eng
Citation
Nat Rev Clin Oncol, 14 (5), pp. 284 - 296

Browse

All of ICR repositoryICR Divisions & RM Clinical UnitsIssue dateAuthorsTitlesSubjectsThis collectionIssue dateAuthorsTitlesSubjects

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.